Laboratory Market Ricerca

---

Table of Contents

Laboratory Market Ricerca: How Diagnostics Leaders Win in a Consolidating Market

Laboratory market research has shifted from procurement support to strategic intelligence that shapes capital allocation, M&A targeting, and platform positioning. The buyers who fund clinical labs, reference networks, and IVD platforms now demand evidence at the segment level: which assays compound, which payer mixes hold, which regional networks defend pricing.

The diagnostics sector rewards firms that read three signals early: reimbursement trajectory, clinician adoption velocity, and consolidation pressure inside hospital outreach networks. Laboratory market research that connects these signals to a launch sequence or acquisition thesis produces measurable upside. Research that stops at sizing does not.

What Laboratory Market Research Delivers to Diagnostics Strategy

Laboratory market research is the structured analysis of clinical lab demand, IVD platform competition, payer reimbursement, and channel economics across hospital outreach, independent reference labs, physician office labs, and direct-to-consumer testing. It informs market access strategy, launch sequencing, indication prioritization, and platform investment decisions.

The work spans three distinct buyers. IVD manufacturers (Roche Diagnostics, Abbott, Siemens Healthineers, Danaher’s Beckman and Cepheid units) need installed base analytics and menu expansion economics. Reference labs (Quest, LabCorp, Sonic Healthcare, Eurofins) need volume migration intelligence and contract defensibility data. Health systems running outreach programs need outreach revenue strategy and payer mix modeling.

Each buyer reads the same market through a different lens. Strong research output speaks to the specific decision: instrument placement strategy for the manufacturer, hospital outreach contract retention for the reference lab, send-out reduction analysis for the integrated delivery network.

The Reimbursement Signal Most Sizing Studies Miss

PAMA-driven CLFS rate revisions, MolDX coverage decisions, and Z-code registration patterns move lab economics more than headline volume growth. A molecular assay can double in test volume while net revenue per test compresses 30 percent under updated gapfill pricing. Sizing models built on test counts misread the opportunity.

The better approach reads coverage and coding together. CPT category I migration timing, PLA code adoption, and local coverage determinations from MolDX and Novitas predict which assays cross the threshold from cash-pay or hospital-absorbed cost to reimbursed standard of care. That threshold is where adoption curves accelerate.

According to SIS International Research, IVD and reference lab clients increasingly request real-world evidence frameworks that link clinician ordering patterns to payer coverage windows, because the gap between FDA clearance and reimbursed adoption now determines launch ROI more than clinical performance alone.

Where Diagnostics Leaders Find Compounding Growth

Five segments concentrate the upside. Each rewards a different intelligence approach.

Molecular and companion diagnostics. Oncology Dx (Guardant, Natera, Exact Sciences, Foundation Medicine) and infectious disease panels carry the highest margin per accession. Win/loss analysis at the KOL level, indication prioritization, and payer value story development drive launch outcomes.

Lab automation and middleware. Total lab automation lines from Roche, Abbott, Beckman, and Inpeco compete on uptime, menu breadth, and LIS integration. Buyers need installed base analytics and total cost of ownership modeling against five-to-seven-year reagent contracts.

Decentralized and point-of-care testing. POC molecular (Cepheid, BioFire, Cue, Visby) is reshaping ED and urgent care economics. Sizing requires site-of-service modeling, not channel sizing.

Specialty and esoteric reference. ARUP, Mayo Clinic Laboratories, and Sonic networks defend margin through esoteric menu and pathology subspecialty depth. Send-out economics inside health systems determine retention.

Direct-to-consumer and employer testing. Quest, LabCorp, and Everlywell channel growth depends on retail partnership economics and CLIA-waived test menu evolution.

Source: SIS International Research

The Methodology Mix That Produces Defensible Answers

Diagnostics decisions sit on a four-source intelligence base. No single source carries the weight.

B2B expert interviews with lab directors, pathologists, and payer medical directors surface the coverage logic and ordering criteria that public data omits. Quantitative surveys of ordering clinicians size demand and price sensitivity at the indication level. Competitive intelligence on IVD pipelines, MolDX submissions, and clinical trial registries maps the menu eighteen to thirty-six months out. Ethnographic observation inside core lab and microbiology workflows identifies adoption barriers that surveys never capture.

SIS International’s mixed-method engagements in healthcare and diagnostics, including structured fieldwork across Latin American clinical lab networks, have shown that triangulating clinician demand signals with payer coverage timelines and reference lab procurement cycles produces materially different launch sequences than single-source models.

Geographic Asymmetry Creates the Real Opportunity

Laboratory market research at the global level rewards firms that read regional structure precisely. The United States runs on payer fragmentation and CLFS pricing pressure. Western Europe runs on tender cycles and national reimbursement bodies. Brazil, Mexico, and the Gulf operate through distributor-led IVD channels where instrument placement economics differ sharply from direct markets. Japan’s SRL, BML, and LSI Medience structure mirrors a consolidated reference model with distinct pricing logic.

The asymmetry creates entry opportunity. An assay losing pricing power in the US under gapfill revision can hold premium economics in private-pay Brazilian networks or GCC reference labs for years. Multi-country sizing without channel-level economics misses this entirely.

The SIS Diagnostics Intelligence Framework

Four lenses, applied in sequence, convert raw lab market data into a decision:

1. Coverage trajectory. Where does the assay sit on the path from cash-pay to PLA code to category I CPT to LCD coverage?

2. Channel economics. What does the test earn net of bad debt, send-out cost, and reagent commitment across hospital outreach, reference, and POC?

3. Adoption velocity. Which KOLs and integrated networks set the ordering pattern, and what is the lag from guideline inclusion to volume?

4. Consolidation pressure. Where are reference networks acquiring outreach books, and which regional labs are takeout candidates?

Strategy teams that move through these four lenses build acquisition theses and launch plans that hold up under board scrutiny.

What Separates Strong Laboratory Market Research from Reports

The diagnostics buyers who get the most from laboratory market research treat it as decision infrastructure, not deliverable inventory. They commission research tied to a specific gate: a CapEx approval on automation, an in-licensing decision on a molecular menu, an entry sequence across three Latin American markets, a defense plan against a national reference lab encroaching on outreach contracts. The research output is read by the people who sign the check.

That orientation produces compounding returns. Laboratory market research connected to a real decision builds an evidence base the organization reuses across the next three engagements. Generic reports do not.

A proposito di SIS Internazionale

SIS Internazionale offre ricerca quantitativa, qualitativa e strategica. Forniamo dati, strumenti, strategie, report e approfondimenti per il processo decisionale. Conduciamo anche interviste, sondaggi, focus group e altri metodi e approcci di ricerca di mercato. Contattaci per il tuo prossimo progetto di ricerca di mercato.